Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Statement [Abstract]
Revenue	$ 50,000	$ 404,000	$ 50,000	$ 523,000
Grant revenue	575,000		575,000
Costs and expenses:
Cost of revenue	2,000	8,000	2,000	199,000
Research and development	7,334,000	6,543,000	17,300,000	21,259,000
General and administrative	1,872,000	1,531,000	5,565,000	4,741,000
Total costs and expenses	9,208,000	8,082,000	22,867,000	26,199,000
Loss from operations	(8,583,000)	(7,678,000)	(22,242,000)	(25,676,000)
Interest expense	(148,000)		(150,000)
Other income (expense), net	(23,000)	36,000	(14,000)	139,000
Loss before provision for income taxes	(8,754,000)	(7,642,000)	(22,406,000)	(25,537,000)
Provision for income taxes	0	0	0	0
Net loss	(8,754,000)	(7,642,000)	(22,406,000)	(25,537,000)
Net loss attributable to noncontrolling interests	0	0	0	0
Net loss attributable to Vaccinex, Inc. common stockholders	(8,754,000)	(7,642,000)	(22,406,000)	(25,537,000)
Comprehensive loss	$ (8,754,000)	$ (7,642,000)	$ (22,406,000)	$ (25,537,000)
Net loss per share attributable to Vaccinex, Inc. common stockholders, basic and diluted	$ (0.44)	$ (0.56)	$ (1.27)	$ (2.09)
Weighted-average shares used in computing net loss per share attributable to Vaccinex, Inc. common stockholders, basic and diluted	20,074,726	13,759,602	17,587,219	12,246,599